Skip to main content

SCLC,Extensive Stage

5
Pipeline Programs
7
Companies
5
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

7 companies ranked by most advanced pipeline stage

UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
1
IBI363（PD-1/IL-2a-bias）Phase 21 trial
Active Trials
NCT07289048Not Yet Recruiting35Est. Dec 2028
ViiV Healthcare
ViiV HealthcareNC - Durham
1 program
1
NiraparibPhase 2
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Pembrolizumab/OlaparibPhase 2
MSD
MSDIreland - Ballydine
1 program
1
Pembrolizumab/OlaparibPhase 21 trial
Active Trials
NCT05623319Recruiting60Est. Jul 2027
RayzeBio
RayzeBioCA - San Diego
1 program
1
RYZ101 Dose Level 1Phase 11 trial
Active Trials
NCT05595460Active Not Recruiting21Est. Jul 2027
Chipscreen Biosciences
Chipscreen BiosciencesChina - Shenzhen
1 program
AK104 IV infusion；Chiauranib oralPHASE_1_21 trial
Active Trials
NCT05505825Completed36Est. Jul 2024
GSK
GSKLONDON, United Kingdom
1 program
NiraparibPHASE_21 trial
Active Trials
NCT05718323Recruiting44Est. Jun 2027

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
UNION therapeuticsIBI363（PD-1/IL-2a-bias）
GSKNiraparib
MSDPembrolizumab/Olaparib
Chipscreen BiosciencesAK104 IV infusion；Chiauranib oral
RayzeBioRYZ101 Dose Level 1

Clinical Trials (5)

Total enrollment: 196 patients across 5 trials

NCT07289048UNION therapeuticsIBI363（PD-1/IL-2a-bias）

A Prospective, Single-Arm, Exploratory Study of IBI363 in ES-SCLC Patients After Immunotherapy Progression

Start: Dec 2025Est. completion: Dec 202835 patients
Phase 2Not Yet Recruiting
NCT05718323GSKNiraparib

Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC

Start: Dec 2023Est. completion: Jun 202744 patients
Phase 2Recruiting
NCT05623319MSDPembrolizumab/Olaparib

Pembrolizumab and Olaparib Treatment of Extensive Small Cell Lung Cancer (ES-SCLC)

Start: Mar 2023Est. completion: Jul 202760 patients
Phase 2Recruiting
NCT05505825Chipscreen BiosciencesAK104 IV infusion；Chiauranib oral

A Study of AK104 in Combination With Chiauranib in Patients With Extensive Stage Small Cell Lung Cancer

Start: Aug 2022Est. completion: Jul 202436 patients
Phase 1/2Completed
NCT05595460RayzeBioRYZ101 Dose Level 1

Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Start: Oct 2022Est. completion: Jul 202721 patients
Phase 1Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 196 patients
7 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.